ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS

In proof-of-concept research during our Phase 1 project, we chose 10 important immune targets to discover MAbs. Our strategy was to select for pan-reactive MAbs that bind to conserved mammalian epitopes among three diverse species that span the mammalian tree (marmoset, minipig, and ferret). Our results demonstrate that we were able to generate robust titers against nearly all of our target proteins, that most titers cross-reacted with all 3 divergent species, and that we were able to isolate MAbs that cross-react with multiple mammalian species, exactly as designed. To date we have isolated 135 sequence-unique antibodies that bind to 7 different immune targets across 11 mammalian species. This panel of 135 unique MAbs function by flow cytometry, cross-react with many (and in some cases all) mammalian species tested, and are in the process of being characterized for other common applications. This Phase 2 project will continue these efforts to discover pan-reactive MAbs for 13 under-represented mammalian animal models against 24 additional immune targets where quality research reagents are lacking. Project Number: 75N93025C00019-0-9999-1 | Fiscal Year: 2025 | NIH Institute/Center: National Institute of Allergy and Infectious Diseases (NIAID) | Principal Investigator: ROSS CHAMBERS | Institution: INTEGRAL MOLECULAR, PHILADELPHIA, PA | Award Amount: $1,500,000 | Activity Code: N44 View on NIH RePORTER: https://reporter.nih.gov/project-details/75N93025C00019099991